AU2013215269A1 - Beta-arrestin effectors and compositions and methods of use thereof - Google Patents

Beta-arrestin effectors and compositions and methods of use thereof Download PDF

Info

Publication number
AU2013215269A1
AU2013215269A1 AU2013215269A AU2013215269A AU2013215269A1 AU 2013215269 A1 AU2013215269 A1 AU 2013215269A1 AU 2013215269 A AU2013215269 A AU 2013215269A AU 2013215269 A AU2013215269 A AU 2013215269A AU 2013215269 A1 AU2013215269 A1 AU 2013215269A1
Authority
AU
Australia
Prior art keywords
peptide
pro
mod
res
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013215269A
Other languages
English (en)
Inventor
Xia Tao Chen
Dennis Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevena Inc
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of AU2013215269A1 publication Critical patent/AU2013215269A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013215269A 2012-01-31 2013-01-30 Beta-arrestin effectors and compositions and methods of use thereof Abandoned AU2013215269A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592887P 2012-01-31 2012-01-31
US61/592,887 2012-01-31
PCT/US2013/023808 WO2013116312A1 (en) 2012-01-31 2013-01-30 ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
AU2013215269A1 true AU2013215269A1 (en) 2014-08-21

Family

ID=48870731

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013215269A Abandoned AU2013215269A1 (en) 2012-01-31 2013-01-30 Beta-arrestin effectors and compositions and methods of use thereof

Country Status (14)

Country Link
US (2) US8946142B2 (cg-RX-API-DMAC7.html)
EP (1) EP2809337A4 (cg-RX-API-DMAC7.html)
JP (1) JP6225121B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140132340A (cg-RX-API-DMAC7.html)
CN (1) CN104168907A (cg-RX-API-DMAC7.html)
AU (1) AU2013215269A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014018709A8 (cg-RX-API-DMAC7.html)
CA (1) CA2862933A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491455A1 (cg-RX-API-DMAC7.html)
HK (1) HK1203379A1 (cg-RX-API-DMAC7.html)
IL (1) IL233826A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014009233A (cg-RX-API-DMAC7.html)
NZ (1) NZ627995A (cg-RX-API-DMAC7.html)
WO (1) WO2013116312A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116312A1 (en) * 2012-01-31 2013-08-08 Trevena, Inc. ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
EP3208861A1 (en) 2016-02-19 2017-08-23 Novaled GmbH Electron transport layer comprising a matrix compound mixture for an organic light-emitting diode (oled)
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925345A (en) * 1974-05-10 1975-12-09 Francis Merlin Bumpus (sar' 1',thr' 8'+9 angiotensin ii as an angiotensin antagonist
US3932624A (en) 1974-06-17 1976-01-13 Morton-Norwich Products, Inc. Method for prolonging the inhibitory effect of saralasin on angiotensin II
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4547489A (en) 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds
US5182264A (en) 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
DE68903907T2 (de) * 1988-09-05 1993-06-09 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
GB8822483D0 (en) 1988-09-24 1988-10-26 Medical Res Council Developments relating to mas oncogene
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
EP0608212A1 (en) 1990-08-27 1994-08-03 Peptide Technology Ltd Method of treating viral infection
EP0498361A3 (en) 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
PT730465E (pt) 1993-09-24 2002-06-28 Univ Southern California Utilizacao de angiotensina iii e de analogos desta em cicatrizacao de tecidos
US5958884A (en) 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
ATE268782T1 (de) 1997-12-12 2004-06-15 Univ Southern California Zusammensetzungen zur wundheilung
US20040214836A1 (en) 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20050202029A1 (en) 2003-10-03 2005-09-15 The Board Of Trustees Of The Leland Stanford Junior University Family of cystatin-related chemoattractant proteins
US20070286863A1 (en) 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
WO2008130217A1 (en) 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
GB0705488D0 (en) 2007-03-22 2007-05-02 Isis Innovation Treatment of inflammation and/or endotoxic shock
US8038992B2 (en) 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
US20100092974A1 (en) 2008-08-15 2010-04-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for modulators of ccrl2
NZ594302A (en) * 2008-12-29 2013-07-26 Trevena Inc Beta-arrestin effectors and compositions and methods of use thereof
US8293925B2 (en) 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
CA2802952A1 (en) * 2010-06-24 2011-12-29 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
WO2013116312A1 (en) * 2012-01-31 2013-08-08 Trevena, Inc. ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
MX2014009233A (es) 2015-05-15
HK1203379A1 (en) 2015-10-30
US20130196902A1 (en) 2013-08-01
BR112014018709A8 (pt) 2017-07-11
EP2809337A1 (en) 2014-12-10
JP2015506960A (ja) 2015-03-05
WO2013116312A1 (en) 2013-08-08
KR20140132340A (ko) 2014-11-17
BR112014018709A2 (cg-RX-API-DMAC7.html) 2017-06-20
CA2862933A1 (en) 2013-08-08
EA201491455A1 (ru) 2015-01-30
IL233826A0 (en) 2014-09-30
JP6225121B2 (ja) 2017-11-01
CN104168907A (zh) 2014-11-26
US8946142B2 (en) 2015-02-03
NZ627995A (en) 2016-12-23
US20150105316A1 (en) 2015-04-16
EP2809337A4 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
US8809260B2 (en) β-arrestin effectors and compositions and methods of use thereof
Gerbier et al. Development of original metabolically stable apelin‐17 analogs with diuretic and cardiovascular effects
ES2819825T3 (es) Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso
US8946142B2 (en) Beta-arrestin effectors and compositions and methods of use thereof
Axelband et al. Ang-(3–4) suppresses inhibition of renal plasma membrane calcium pump by Ang II
US20240025949A1 (en) Beta-Arrestin Effectors and Compositions and Methods of Use Thereof
WO2016196750A1 (en) Beta-arrestin effectors and compositions and methods of use thereof
US20210324005A1 (en) Beta-Arrestin Effectors and Compositions and Methods of Use Thereof
HK1162955B (en) Beta-arrestin effectors and compositions and methods of use thereof
US7414029B2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
Jensen et al. Structure-activity relationships of trout bradykinin ([Arg0, Trp5, Leu8]-bradykinin])
Deshotels Modulation of angiotensin-converting enzyme 2 (ACE2) expression, subcellular localization, and enzymatic activity by angiotensin II: Implication in neurogenic hypertension
EP1878741A2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application